17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterisation of an epigenetically altered CD4 + CD28 + Kir + T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Antigen-specific CD4 + T cells epigenetically modified with DNA methylation inhibitors overexpress genes normally suppressed by this mechanism, including CD11a, CD70, CD40L and the KIR gene family. The altered cells become autoreactive, losing restriction for nominal antigen and responding to self-class II major histocompatibility complex (MHC) molecules without added antigen, and are sufficient to cause a lupus-like disease in syngeneic mice. T cells overexpressing the same genes are found in patients with active lupus. Whether these genes are co-overexpressed on the same or different cells is unknown. The goal of this study was to determine whether these genes are overexpressed on the same or different T cells and whether this subset of CD4 + T cells is also present in patients with lupus and other rheumatic diseases.

          Methods

          Multicolour flow cytometry was used to compare CD11a, CD70, CD40L and KIR expression on CD3 +CD4 +CD28 + T cells to their expression on experimentally demethylated CD3 +CD4 +CD28 + T cells and CD3 +CD4 +CD28 + T cells from patients with active lupus and other autoimmune diseases.

          Results

          Experimentally demethylated CD4 + T cells and T cells from patients with active lupus have a CD3 +CD4 +CD28 +CD11a hiCD70 +CD40L hiKIR + subset, and the subset size is proportional to lupus flare severity. A similar subset is found in patients with other rheumatic diseases including rheumatoid arthritis, systemic sclerosis and Sjögren's syndrome but not retroperitoneal fibrosis.

          Conclusions

          Patients with active autoimmune rheumatic diseases have a previously undescribed CD3 +CD4 +CD28 +CD11a hiCD70 +CD40L hiKIR + T cell subset. This subset may play an important role in flares of lupus and related autoimmune rheumatic diseases, provide a biomarker for disease activity and serve as a novel therapeutic target for the treatment of lupus flares.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: not found
          • Article: not found

          Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

          M Hochberg (1997)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

            To develop a disease activity index for patients with primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index (ESSDAI). Thirty-nine SS experts participated in an international collaboration, promoted by EULAR, to develop the ESSDAI. Experts identified 12 organ-specific 'domains' contributing to disease activity. For each domain, features of disease activity were classified in three or four levels according to their severity. Data abstracted from 96 patients with systemic complications of primary SS were used to generate 702 realistic vignettes for which all possible systemic complications were represented. Using the 0-10 physician global assessment (PhGA) scale, each expert scored the disease activity of five patient profiles and 20 realistic vignettes. Multiple regression modelling, with PhGA used as the dependent variable, was used to estimate the weight of each domain. All 12 domains were significantly associated with disease activity in the multivariate model, domain weights ranged from 1 to 6. The ESSDAI scores varied from 2 to 47 and were significantly correlated with PhGA for both real patient profiles and realistic vignettes (r=0.61 and r=0.58, respectively, p<0.001). Compared with 57 (59.4%) of the real patient profiles, 468 (66.7%) of the realistic vignettes were considered likely or very likely to be true. The ESSDAI is a clinical index designed to measure disease activity in patients with primary SS. Once validated, such a standardised evaluation of primary SS should facilitate clinical research and be helpful as an outcome measure in clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Oxidative stress in the pathology and treatment of systemic lupus erythematosus.

              Oxidative stress is increased in systemic lupus erythematosus (SLE), and it contributes to immune system dysregulation, abnormal activation and processing of cell-death signals, autoantibody production and fatal comorbidities. Mitochondrial dysfunction in T cells promotes the release of highly diffusible inflammatory lipid hydroperoxides, which spread oxidative stress to other intracellular organelles and through the bloodstream. Oxidative modification of self antigens triggers autoimmunity, and the degree of such modification of serum proteins shows striking correlation with disease activity and organ damage in SLE. In T cells from patients with SLE and animal models of the disease, glutathione, the main intracellular antioxidant, is depleted and serine/threonine-protein kinase mTOR undergoes redox-dependent activation. In turn, reversal of glutathione depletion by application of its amino acid precursor, N-acetylcysteine, improves disease activity in lupus-prone mice; pilot studies in patients with SLE have yielded positive results that warrant further research. Blocking mTOR activation in T cells could conceivably provide a well-tolerated and inexpensive alternative approach to B-cell blockade and traditional immunosuppressive treatments. Nevertheless, compartmentalized oxidative stress in self-reactive T cells, B cells and phagocytic cells might serve to limit autoimmunity and its inhibition could be detrimental. Antioxidant therapy might also be useful in ameliorating damage caused by other treatments. This Review thus seeks to critically evaluate the complexity of oxidative stress and its relevance to the pathogenesis and treatment of SLE.
                Bookmark

                Author and article information

                Journal
                Lupus Sci Med
                Lupus Sci Med
                lupusscimed
                lupus
                Lupus Science & Medicine
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2053-8790
                2016
                4 April 2016
                : 3
                : 1
                : e000147
                Affiliations
                [1 ]Rheumatology Division, Department of Internal Medicine, The University of Michigan Medical School , Ann Arbor, Michigan, USA
                [2 ]Eli Lilly and Company , San Diego, California, USA
                [3 ]Department of Environmental Health Sciences, The University of Michigan , Ann Arbor, Michigan, USA
                [4 ]Department of Obstetrics & Gynecology, The University of Michigan Medical School , Ann Arbor, Michigan, USA
                [5 ]Biomedical Research Core, Flow Cytometry, The University of Michigan , Ann Arbor, Michigan, USA
                [6 ]Department of Medicine, Ann Arbor VA Medical Center , Ann Arbor, Michigan, USA
                Author notes
                [Correspondence to ] Dr Faith M Strickland; fmstrick@ 123456umich.edu
                Author information
                http://orcid.org/0000-0003-1412-4453
                Article
                lupus-2016-000147
                10.1136/lupus-2016-000147
                4823547
                27099767
                68757856-2018-4045-b13e-95e693ac8ce7
                Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

                This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                : 20 January 2016
                : 8 March 2016
                : 9 March 2016
                Funding
                Funded by: Lupus Foundation of America, http://dx.doi.org/10.13039/100002193;
                Award ID: Insight Prize
                Funded by: National Institute of Environmental Health Sciences, http://dx.doi.org/10.13039/100000066;
                Award ID: 017885
                Award ID: K01 019909
                Funded by: Center for Integrated Healthcare, U.S. Department of Veterans Affairs, http://dx.doi.org/10.13039/100006812;
                Award ID: Merit
                Funded by: National Institute of Allergy and Infectious Diseases, http://dx.doi.org/10.13039/100000060;
                Award ID: 110502
                Funded by: National Institute of Child Health and Human Development, http://dx.doi.org/10.13039/100000071;
                Award ID: K12 001438
                Funded by: National Institute of Arthritis and Musculoskeletal and Skin Diseases, http://dx.doi.org/10.13039/100000069;
                Award ID: 42525
                Award ID: K24 063120
                Categories
                Biomarker Studies
                1506
                2253

                systemic lupus erythematosus,t cells,kir,autoimmune diseases,dna methylation

                Comments

                Comment on this article